OliX Pharmaceuticals Inc (KOSDAQ:226950), a pharmaceutical company based in South Korea, said on Wednesday that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to develop its RNAi therapeutic OLX10212 for the treatment of age-related macular degeneration (AMD).
OLX10212 targets inflammation pathways that play a key role in the development of geographic atrophy (GA) and neovascular AMD. The primary objective of the phase 1 study is to evaluate the safety and tolerability of OLX10212 in patients with AMD.
With the FDA approval of the IND application for OLX10212, OliX has initiated clinical trials for two investigational therapeutic programmes in the US. In June 2022 the company completed patient enrolment for the Phase 2a clinical trial of OLX10010, for the treatment of hypertrophic scarring.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax